Clinical Cancer Research · 2005 · 134 citations · 39 references
MedicineImmunologyOncologyClinical ImmunologyMolecular OncologyTransplant ImmunologyConditioning RegimensReduced-intensity ConditioningAllogeneic Transplant ConditioningChronic Lymphocytic Leukemia TherapyConditioning Regimen IntensityCytogenetic AberrationsHeavy Chain Variable Region GenesImmunoglobulin Heavy Chain LocusImmunoglobulin Heavy Chain RearrangementTransplantation Outcome Assessment
PURPOSE: To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics. EXPERIMENTAL DESIGN: Eighty-three percent of patients had active disease at the moment of transplant. That is, 14 of the 23 patients analyzed (60%) had unmutated immunoglobulin variable heavy-chain gene (IgV(H)) status; 8 of 25 patients (32%) had 11q-, with four of them also displaying unmutated IgV(H); and six (24%) had 17p- (five were also unmutated). RESULTS: After a median follow-up of 47.3 months, all 22 patients alive are disease free; overall survival and event-free survival (EFS) at 6 years were 70% and 72%, respectively. According to molecular/cytogenetic characteristics, overall survival and EFS for unmutated CLL and/or with 11q- aberration (n = 13) were 90% and 92%, respectively, not significantly different to those with normal in situ hybridization, 13q- and +12, or mutated CLL (n = 7). All six patients with 17p deletion were transplanted with active disease, including three with refractory disease; all except one reached complete remission after the transplant and two are alive and disease free. Nonrelapse mortality (NRM) was 20%; more than two lines before transplant is an independent prognostic factor for NRM (P = 0,02), EFS (P = 0.02), and overall survival (P = 0.01). Patients older than 55 years have a higher risk of NRM (hazard ratio, 12.8; 95% confidence interval, 1.5-111). Minimal residual disease was monitored by multiparametric flow cytometry in 21 patients. Clearance of CD79/CD5/CD19/CD23 cells in bone marrow was achieved in 68% and 94% of the patients at days 100 and 360, respectively. CONCLUSION: According to these results, RIC allogeneic transplant could overcome the adverse prognosis of patients with unmutated CLL as well as those with 11q- or 17p-.
39
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations
Life Sciences, Genetics, Oncology +17
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.9K citations · Full text
Medicine, Hematology, Oncology +17